Immuneering to Present at the Leerink Global Healthcare Conference

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments aimed at improving patient survival and quality of life [2] Company Overview - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, which aim to enhance overall survival through three mechanisms: durable tumor shrinkage with reduced resistance, counteracting cachexia to preserve body mass, and minimizing side effects to improve performance status and combinability [2] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, targeting various cancer indications, particularly MAPK pathway-driven tumors like pancreatic cancer [2] - The company plans to initiate dosing for the MAPKeeper 301 trial in mid-2026, a pivotal Phase 3 study evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [2] Upcoming Events - Immuneering's management will present at the Leerink Global Healthcare Conference in Miami, Florida, from March 9-11, 2026, with CEO Ben Zeskind discussing the company's pipeline, platform, and business strategy [1]